SJH_17-001

BMS CA209-722 (CheckMate 722): Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation, T790M Negative Who Failed 1L EGFR Tyrosine Kinase Inhibitor Therapy

The purpose of this study is to determine whether Nivolumab+ chemotherapy and Nivolumab+Ipilimumab is effective in the treatment of patients with EGFR mutation, T790M negative NSCLC who failed first line (1L) EGFR TKI therapy
Phase III
NCT02864251
All Other|Cancer
Lung
Timothy Byun, M.D.
BMS (Bristol-Myers Squibb)
Lavinia Dobrea
  • St. Joseph Hospital of Orange
  • xSJH Southern California